Get Premium to unlock powerful stock data

Meridian Bioscience Inc (VIVO) Files 10-K for the Fiscal Year Ended on September 30, 2021

Author's Avatar
insider
Nov 23, 2021
Article's Main Image

Meridian Bioscience Inc (

VIVO, Financial)(30-Year Financial) files //www.sec.gov/Archives/edgar/data/794172/000119312521337663/0001193125-21-337663-index.htm'' rel='nofollow' target='_blank'>its latest 10-K with SEC for the fiscal year ended on September 30, 2021.

For the last quarter Meridian Bioscience Inc reported a revenue of $76.2 million, compared with the revenue of $64.15 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $317.9 million, an increase of 25.3% from last year. For the complete 30-year financial data, please go here.. For the last five years Meridian Bioscience Inc had an average revenue growth rate of 9.1% a year.

The reported diluted earnings per share was $1.62 for the year, an increase of 51.4% from previous year. Over the last five years Meridian Bioscience Inc had an EPS growth rate of 18.8% a year. The Meridian Bioscience Inc enjoyed an operating margin of 29.1%, compared with the operating margin of 23.5% a year before. The 10-year historical median operating margin of Meridian Bioscience Inc is 26.82%. The profitability rank of the company is 8 (out of 10).

At the current stock price of $21.26, Meridian Bioscience Inc is traded at 21.9% discount to its historical median P/S valuation band of $27.22. The P/S ratio of the stock is 2.94, while the historical median P/S ratio is 3.94. The stock gained 12.63% during the past 12 months.

For the complete 20-year historical financial data of VIVO, click here.

You may also like :

  1. VIVO Guru Trades
  2. VIVO 10-Year Financials and charts
  3. VIVO DCF Calculation
  4. VIVO 10-Year Valuations
  5. VIVO Insider Trade
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus